Prolytix’s Post

Revolutionize Your Rheumatoid Arthritis Research! Discover how Central BioHub’s high-quality biospecimen can enhance your autoimmune and rheumatoid arthritis (RA) studies! We provide serum, plasma and urine samples that are tested for common RA specific lab parameters like anti-CCP, RF, CRP, ESR and others, ensuring they meet the rigorous demands of your research. Sample Specifications 🧪 – ·     Matrix: Serum, Plasma, Urine ·     Lab Parameter: anti-Cyclic citrullinated peptide (CCP) / anti-Citrullinated protein antibodies (ACPA) | Rheumatoid factor (RF) | C-reactive protein (CRP) | Erythrocyte sedimentation rate (ESR) | ·     ICD-10: M05. + | M06. + Explore our online marketplace and discover how Central BioHub's Rheumatoid Arthritis samples can make a difference. ·     https://lnkd.in/eGwyE-PX #ResearchAndDevelopment #Biobanking #Diagnostics #Onlinemarketplace #DrugDiscovery #BiomedicalResearch #ClinicalResearch #IVD #Biotechnology #Healthcare #Pharma #Biomedicine

Uncovering the Mechanism Behind the Long-Acting Insulin Icodec's Stability and Clearance 🔍 Researchers at Novo Nordisk have developed Insulin icodec, a novel once-weekly insulin analogue with a half-life of approximately 7 days, by reducing insulin receptor affinity and enhancing albumin binding. This study identifies a key clearance mechanism in which insulin molecules are split into A-chain and B-chain via a thiol–disulphide exchange reaction. Although Insulin icodec is designed to resist this degradation, traces of free B-chain were detected in plasma samples from minipigs and individuals with type 2 diabetes. Stabilizing the insulin against this reaction significantly contributes to Insulin icodec's extended pharmacokinetic and pharmacodynamic profile. 📖 Learn More: https://lnkd.in/eFcRRuHV. Check out the Chirascan Q100 used in this study: https://bit.ly/3SL78Sc. #InsulinIcodec #Diabetes #Pharmacokinetics

The Chinese hamster ovary (CHO) cell is pivotal in producing recombinant therapeutic proteins and monoclonal antibodies due to its human-like glycosylation capabilities. Traditionally, culturing CHO cells involves using fetal bovine serum (FBS) to support cell growth, but FBS poses challenges such as high cost, variability, and contamination risks. Consequently, there's a significant push toward developing serum-free media and alternatives to FBS. This review explores the benefits of CHO cells, high-density expression techniques, and new serum substitutes from human platelet lysates to animal-free extracts, enhancing culture performance and protein production https://lnkd.in/dVyXb3eH

Daprodustat (JESDUVROQ): The First HIF-PHD Inhibitor Approved for Anemia in the US | https://lnkd.in/gwhaXM7M GSK's daprodustat is the first HIF-prolyl hydroxylase domain (PHD) inhibitor approved for the treatment of anemia in chronic kidney disease (CKD) on dialysis in the US. PHDs have been attractive targets for treating anemia, especially in CKD patients, because the enzymes regulate levels of hypoxia-inducible factors (HIFs) including HIF-2, which induces the production of erythropoietin that in turn stimulates red blood cell production. This article highlights why HIF-PHDs are anemia targets, how daprodustat mimics the natural co-factor 2-oxoglutarate, and how the small molecule drug has similar safety and activity as epoetin alfa, an injected biologic. Article | https://lnkd.in/gwhaXM7M

Did you know that #Ceftobiprole (a recently approved #antibiotics) is the active component of the prodrug ceftobiprole medocaril? #Prodrug Activation: Conversion of the prodrug ceftobiprole medocaril into the active compound ceftobiprole happens rapidly and is facilitated by non-specific plasma esterases. Since ceftobiprole medocaril is administered intravenously, active ceftobiprole has minimal (16%) binding to plasma proteins. The half-life of active ceftobiprole following multiple-dose administration is approximately 3.3 hours. #Mechanism of #Action: Ceftobiprole, the active component of ceftobiprole medocaril, demonstrates its bactericidal activity by inhibiting bacterial cell wall synthesis. This activity occurs through binding to essential penicillin-binding proteins (PBPs) and inhibiting their transpeptidase activity, which is crucial for the synthesis of the peptidoglycan layer of the bacterial cell wall. Ceftobiprole exhibits in vitro activity against both Gram-positive and Gram-negative bacteria. In Gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA), ceftobiprole binds to PBP2a. It also binds to PBP2b in Streptococcus pneumoniae (penicillin-intermediate), PBP2x in S. pneumoniae (penicillin-resistant), and to PBP5 in Enterococcus faecalis. For further details, you can explore more information about Ceftobiprole at [DrugBank](https://lnkd.in/dQrgumG5) and [FDA's official announcement] (https://lnkd.in/dkqeJ-E9).

#Mechanisms of Antibiotics 🦠🧫 1. Inhibition of cell wall synthesis: Certain antibiotics, such as penicillins, cephalosporins, and vancomycin, interfere with the synthesis of bacterial cell walls. They target enzymes involved in cell wall synthesis, leading to weakened cell walls, cell lysis, and bacterial death. 2. Inhibition of protein synthesis: Antibiotics like macrolides, tetracyclines, and aminoglycosides target bacterial ribosomes, the cellular structures responsible for protein synthesis. By binding to ribosomal subunits or interfering with protein elongation, these antibiotics prevent bacteria from producing essential proteins, ultimately leading to bacterial death. 3. Inhibition of nucleic acid synthesis: Some antibiotics, including quinolones and fluoroquinolones, inhibit the synthesis of bacterial DNA or RNA. By interfering with enzymes involved in DNA replication, transcription, or repair, these antibiotics disrupt bacterial nucleic acid synthesis and inhibit bacterial growth. 4. Disruption of

Modulating selective post-translational protein modifications on metabolic regulatory proteins that mediate anti-diabetic action can circumvent potential problems associated with potent direct inhibition of key metabolic proteins. Small molecules selectively inducing peroxisome proliferator-activated receptor-gamma coactivator (PGC)-1α acetylation and inhibiting glucagon-dependent gluconeogenesis causing anti-diabetic effects have been identified. These small molecules selectively suppress the conversion of gluconeogenic metabolites into glucose without interfering with lipogenesis.

Therapeutic application of circular RNA aptamers in a mouse model of psoriasis For smTIRF analysis, LPETG-labeled PKR was pooled and dialyzed overnight in labeling buffer (50 mM Tris-HCl pH 8.0, 500 mM NaCl, 10 mM CaCl2 and 10% glycerol). The protein fractions were then incu bated with sortase and GGGC-Cy3 peptides (for C-terminal labeling, #ChinaPeptides) at 4 °C for 1 h (protein:sortase:peptide, 1:2:5). Labeled PKR was diluted with double volume of buffer C (25 mM HEPES pH 7.8, 1 mM DTT, 10% glycerol and 0.1 mM EDTA) and loaded onto a heparin column, washed with buffer C plus 100 mM NaCl and eluted with buffer C plus 1 M NaCl. PKR-containing fractions were dialyzed in storage buffer (25 mM HEPES pH 7.8, 1 mM DTT, 0.1 mM EDTA, 500 mM NaCl and 20% glycerol) and stored at −80 °C. Concentrations and labeling efficiencies were determined by comparing protein absorbance at 280 nm with Cy3 absorbance at 550 nm and the labeling efficiency was about 50%.

🦠 Introducing the Scrub Typhus IgM/IgG/IgA Card 🦠 👉Scrub typhus is a serious bacterial infection caused by Orientia tsutsugamushi, often spread through bites of infected chiggers (larval mites). Early detection and treatment are crucial to prevent severe complications. 🧪 The Scrub Typhus IgM/IgG/IgA Card is a rapid solid-phase immuno-chromatographic assay designed for the qualitative detection of IgM, IgG, and IgA antibodies. This quick and efficient test helps in identifying the presence of antibodies produced in response to the infection, aiding in timely diagnosis and treatment. 🌐 Learn more about this innovative diagnostic tool and its benefits: Link https://lnkd.in/g2fSrFG8 Stay informed, stay safe! #ScrubTyphus #HealthAwareness #diagnose #RapidTesting #MedicalInnovation #biotech #PublicHealth #ivd #rapidtest

𝐇𝐢𝐠𝐡 𝐭𝐡𝐫𝐨𝐮𝐠𝐡𝐩𝐮𝐭 𝐩𝐥𝐚𝐭𝐟𝐨𝐫𝐦 𝐭𝐞𝐜𝐡𝐧𝐨𝐥𝐨𝐠𝐲 𝐟𝐨𝐫 𝐫𝐚𝐩𝐢𝐝 𝐭𝐚𝐫𝐠𝐞𝐭 𝐢𝐝𝐞𝐧𝐭𝐢𝐟𝐢𝐜𝐚𝐭𝐢𝐨𝐧 𝐢𝐧 𝐩𝐞𝐫𝐬𝐨𝐧𝐚𝐥𝐢𝐳𝐞𝐝 𝐩𝐡𝐚𝐠𝐞 𝐭𝐡𝐞𝐫𝐚𝐩𝐲. As bacteriophages continue to gain regulatory approval for personalized human therapy against antibiotic-resistant infections, there is a need for transformative technologies for rapid target identification through multiple, large, decentralized therapeutic phages biobanks. Here, the authors design a high throughput phage screening platform comprised of a portable library of individual shelf-stable, ready-to-use phages, in all-inclusive solid tablets. Each tablet encapsulates one phage along with luciferin and luciferase enzyme stabilized in a sugar matrix comprised of pullulan and trehalose capable of directly detecting phage-mediated adenosine triphosphate (ATP) release through ATP bioluminescence reaction upon bacterial cell burst. The tablet composition also enhances desiccation tolerance of all components, which should allow easier and cheaper international transportation of phages and as a result, increased accessibility to therapeutic phages. The authors demonstrate high throughput screening by identifying target phages for select multidrug-resistant clinical isolates of Pseudomonas aeruginosa, Salmonella enterica, Escherichia coli, and Staphylococcus aureus with targets identified within 30-120 min. https://lnkd.in/gVNRvMfk